Top

Published in:

01-06-2007 | Original Article

Submicrobial Doxycycline and Rosacea

Author: Ronald D. Wise

Published in: Comprehensive Therapy | Issue 2/2007

Abstract

Rosacea is a disease of inflammation with no pathogenic bacteria involved. Successful treatment of rosacea is possible without using antimicrobial preparations. Oracea™ capsules provide the antiinflammatory benefits of doxycycline without contributing to the development of resistance to doxycycline.

Sande MA, Mandell GL. Antimicrobial agents. In: Gilman, AG, Rall, TW, Nies, AS, Taylor, P, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. McGraw-Hill; 1993. p.1117–25.

Meyers B, Salvatore M. Tetracyclines and chloramphenicol. In: Mandell Gl, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia, PA: Elsevier; 2005. p. 357–66.

Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: Mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992;5(4):38–99.

Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. SKINmed 2003;2(4):234–45, Review.PubMedCrossRef

Baldwin HE. Oral therapy for rosacea. J Drugs Dermatol 2006;5(1):16–21.PubMed

Levy SB. The challenge of antibiotic resistance. Sci Am 1998;278(3):46–53.PubMedCrossRef

Bernstein JM. Treatment of community-acquired pneumonia-IDSA guidelines. Chest 1999;1115:95–135.

Stanford Hospital & Clinics. Antibiotic susceptibility of bacteria and yeasts. Available at: http://med.stanford.edu/lane/schid/susceptibility/ReportB.htm. (Accessed February 10, 2006).

US Food and Drug Administration. FDA publishes final rule to require labeling about antibiotic resistance. FDA News. Available at: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00869.html. (Accessed February 10, 2006).

Powell FC. Rosacea. N Engl J Med 2005;352(8):793–803.PubMedCrossRef

National Rosacea Society. 14 million Americans urged to face up to rosacea before it gets worse. News Releases. April; 1, 2005. Available at: http://www.rosacea.org/press/archive/20050401.html. (Accessed February 10, 2006).

Milliklin L. The proposed inflammatory pathophysiology of rosacea: Implications for treatment. SKINmed 2003;2(1):43–7.CrossRef

Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venerol 1989;69(5):419–23.PubMed

Wilkin J, Dahl M, Detmar M. et al. Standard classification of rosacea. Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2004;50(6):907–12.PubMedCrossRef

Crawford GH, Pelle MT, James, WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004;51(3):327–41.PubMedCrossRef

Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea. Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002;46(4):584–87.PubMedCrossRef

Jansen T, Plewig GJ. Rosacea: classification and treatment. R Soc Med 1997;90(3):144–50.

Buechner SA. Rosacea: An update. Dermatology 2005;201(2):100–8.CrossRef

Bikowski JB. What you should know about subantimicrobial dose doxycycline. Pract Dermatol 2005;2(6):38–43.

Jones D. Reactive oxygen species and rosacea. Cutis 2004;74(Suppl 3):17–20, Review.PubMed

Miyachi Y. Potential antioxidant mechanism of action for metronidazole: Implications for rosacea management. Adv Ther 2001;18(6):237–43.PubMed

Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966;78(12):649–52.PubMedCrossRef

Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54(2):258–65.PubMedCrossRef

Del Russo JQ. The antibiotic paradox: benefits and risks of using antimicrobial oral antibiotics for the systemic treatment of rosacea. Cutis 2004;74(2):118–22.

Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12(2):12–26.PubMedCrossRef

Schroeder K, Lee H, Wolff M, et al. Low-dose tetracyclines (TCs) decrease elastase and beta-glucuronidase activities in gingival crevicular fluid (GCF) [abstract 1090]. J Dent Res 1990;69(special issue):245.

Schroeder KL, Ramamurphy NS, Szczepanek KA, et al. Low–dose tetracycline prevents attachment loss in adult periodontitis [abstract 1936]. J Dent Res 1992;71:758.

Skidmore R, Kovach R, Walker C, et al. Effects of submicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003;39(4):459–64.CrossRef

Del Rosso JQ, Bikowski J. When is an antibiotic not an antibiotic? Skin & Aging. 2004;11:36–42.

Golub LM, Wolff M, Roberts S, et al. Treating periodontal diseases by blocking tissue-destructive enzymes. J Am Dent Assoc 1994;125:163–69 (discussion 169–71).PubMed

Oracea. Newtown, PA: CollaGenex Pharmaceuticals; 2006 (prescribing information).

Title: Submicrobial Doxycycline and Rosacea
Author: Ronald D. Wise
Publication date: 01-06-2007
Publisher: Humana Press Inc
Published in: Comprehensive Therapy / Issue 2/2007
Print ISSN: 0098-8243
Electronic ISSN: 1559-1190
DOI: https://doi.org/10.1007/s12019-007-8003-x

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2007

CME Questions

Editorial

Risk Factors for Acute Retinopathy of Prematurity

Disease-Specific Depression and Outcomes in Chronic Heart Failure: A Propensity Score Analysis

Book Reviews

Hepatitis C: Epidemiology, Diagnosis, and Management

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage